Philip Ebert

Philip Ebert is a Senior Director at Eli Lilly and Company, where they have been focusing on genomics and bioinformatics since 2022. Prior to this role, Philip served as a Senior Research Scientist at the same company from 2014 to 2022 and held various research positions, including a Research Scientist, where they utilized biological and in silico data for drug target validation. Before joining Eli Lilly, Philip was a Research Assistant Professor at Vanderbilt University Medical Center from 2007 to 2008, concentrating on the role of GABAergic function in schizophrenia. Philip earned a Ph.D. in Biomedical Research from UT Southwestern Medical Center and has completed post-doctoral studies in Neuroscience at the University of Pittsburgh and Vanderbilt University.